Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 7/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4310810 | 0.92 | ACHE (0.58) | ACHEF10ACKR3 | |
| SCHEMBL5783190 | 0.86 | ACHE (0.40) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6402770 | 0.86 | ACHE (0.40) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6401407 | 0.86 | ACHE (0.40) | ACHEF10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5783198 | 0.86 | ACHE (0.40) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL5784224 | 0.86 | ACHE (0.40) | ACHEF10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4305880 | 0.86 | ACHE (0.41) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL4311995 | 0.84 | ACHE (0.43) | ACHEF10ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5784441 | 0.84 | ACHE (0.43) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL6404923 | 0.84 | ACHE (0.43) | ACHEF10ACKR3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482472-B2 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2009-01-27 | — | — | US | disclosed |
| US-20080039446-A1 | Substituted isoindoles and their use | BAYER HEALTHCARE AG (DE) | 2008-02-14 | — | — | US | disclosed |
| US-7189738-B2 | Substituted isoindoles and their use thereof | BAYER HEALTHCARE AG (DE) | 2007-03-13 | — | — | US | disclosed |
| EP-1414817-B1 | substituted isoindoles and the use thereof | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039446-A1 | Substituted isoindoles and their use | F2, F12, TFPI2 | ACHE 1206/4885F10 19/4885ACKR3 1721/4885 |
| US-20040215019-A1 | Substituted isoindoles and the e use thereof | F2, F12, F5 | ACHE 1270/4885F10 14/4885ACKR3 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.